Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and ...

The Regeneron alliance also yielded Sanofi’s under-performing cholesterol drug Praluent (alirocumab), which has failed to make much progress in a largely generic market and could soon be facing ...

Two key objectives for Sanofi under Brandicourt are to have a successful debut for cholesterol-lowerer Praluent (alirocumab) and a successful defence of its diabetes franchise, a responsibility ...

The FDA granted orphan designation to Sanofi (SNY) US Services’ rilzabrutinib as a treatment of autoimmune hemolytic anemia, according to a post to the agency’s website. Published first on ...

More than 1,000,000 patients are being treated with Dupixent globally. 1 Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has ...

Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating ...

After hours: February 21 at 5:39:38 PM EST Loading Chart for SNY ...

After hours: February 21 at 7:50:45 PM EST Loading Chart for REGN ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.